Get the app!
Back to Trades
Total Value
$0
Filing Date
Nov 20, 2026
1 transactions

Trade Summary

On Nov 18, 2026, PharmaCyte Biotech, Inc., 10% Owner, reported $0 of Q/C TECHNOLOGIES, INC. (QCLS) across 1 transactions. The filing covers Common stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
QCLS
CIK
0001321834

Insider Information

Role
10% Owner
Location
LAS VEGAS, NV

Filing Details

Filing Date
Nov 20, 2026
Transaction Date
Nov 18, 2026
Accession Number
0001683168-26-009018
Form Type
4

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Nov 18, 2026Common stock4,982,272—Exercise—

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Nov 18, 2026Series G Long-Term Warrants851,304—Exercise—
Nov 18, 2026Series H Convertible Preferred Stock3,000—Other—

Want live alerts when PharmaCyte Biotech, Inc. trades again?

Download Insider Trades to track QCLS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.
  2. (F2)Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.
  3. (F3)Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment.
  4. (F4)Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment.
  5. (F5)On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)

SEC Filing